加载中........
×

MedSci 2020年期刊智能查询系统(2019年度)

期刊关键词: 支持模糊智能搜索,多关键词组合

期刊领域: 可留空

IF范围: 小于 大于 填数字,填写自己想选择的杂志影响因子范围,可留空

排列方式: 文章数量往往与发表的周期有关

注册会员 APP首发更新 在线咨询

    以下是对 J CLIN ONCOL 杂志介绍
    缩写名/全名
    J CLIN ONCOL/journal of clinical oncology
    投稿经验 | 期刊论坛 | Medsci期刊指数 | 中国SCI文章 | 杂志简介 | 杂志主页  | 投稿链接  | PMC链接
    ISSN号 0732-183X
    1527-7755(电子版ISSN)
    被收录情况 Science Citation Index
    Science Citation Index Expanded
    Current Contents - Clinical Medicine
    Current Contents - Life Sciences
    出版周期 Biweekly
    H指数 191 (google发布,2017年度)
    CiteScore分区 所属分类:Biochemistry, Genetics and Molecular Biology - Cancer Research 分区: 4/191|Medicine - Oncology 分区: 5/32
    CiteScore趋势 11.08 (2018年度)
    APP下载
    相关报道 · 【盘点】2020年度J Clin Oncol杂志回顾汇总(三)
    · 【盘点】2020年度J Clin Oncol杂志回顾汇总(二)
    · J Clin Oncol:局部前列腺癌的常规分割放疗和中度低分割放疗比较
    · J Clin Oncol:Canary前列腺积极监测研究(PASS)群体中的17个基因基因组前列腺评分测试结果
    · J Clin Oncol:难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究
    · J Clin Oncol:雄激素阻断治疗和外束放射治疗在局部前列腺癌中的治疗序列研究
    · J Clin Oncol:与种系PALB2致病变异相关的癌症风险研究
    · J Clin Oncol:前列腺癌低分馏辐射或常规分馏辐射治疗后患者报道的功能结果研究
    · Journal of Clinical Oncology:Bemarituzumab治疗晚期胃食管腺癌的I期研究
    · JCO:来自keynote189的最新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果
    出版社或管理机构杂志由  American Society of Clinical Oncology  出版或管理。    ISSN号:0732-183X
    杂志简介/稿件收录要求

    About Journal of Clinical Oncology

    JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published thrice monthly, JCO is the foremost peer-reviewed journal focusing on clinical cancer research and the authoritative source for current information on the diagnosis and treatment of patients with cancer.

    Why publish in Journal of Clinical Oncology?

    We offer rapid publication, high visibility, and the opportunity to have your research widely read.

    Speed of publication

    • Average time from submission to first decision is just 10 days.
    • Articles are published online first, weeks ahead of issue publication.
    • Rapid Communications program that fast-tracks important research.

    Impact and reach

    • Cited more than 133,000 times in 2014—ranked #1 among all clinical oncology journals.(1)
    • 2014 ISI Impact Factor: 18.443(1)
    • Eigenfactor Rank: #1(1)
    • Google Scholar h5-index Rank: #1(2)
    • Over 6.6 million full-text article request each year.
    • Read by more than 25,000 oncologists in over 120 countries.
    • Accessed by nearly 10,000 academic, corporate, and government institutions worldwide.

    Benefits of partnering with ASCO

    • Gain instant recognition by publishing with ASCO, the most trusted source in oncology information.
    • Have your article promoted via ASCO publications, websites, and social media.
    • Take advantage of immediate open access options for your manuscript.

    The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.

    The acceptance rate for Original Reports is 13%.

    JCO is published three times per month -- a total of 36 issues per year.

    JCO provides free, or significantly discounted, online access to public health institutions in more than 100 developing countries through the World Health Organization''''s Health InterNetwork Access to Research Initiative (HINARI). Through HINARI, JCO aims to strengthen public health services by providing public health workers, researchers, and policy makers access to high-quality, relevant, and timely medical information.

    杂志主页/投稿链接journal of clinical oncology 主页  (点击18788次)  | 投稿链接(点击3683次)
    常用链接

    免费全文(pubmed central) | 投稿经验 | Medsci期刊指数 | 杂志主页 | 投稿链接 |

    web对话